Discontinued — last reported Q2 '23
Paychex Acquisitions remained flat by 0.0% to $100.00K in Q4 2025 compared to the prior quarter. Over 4 years (FY 2021 to FY 2025), Acquisitions shows an upward trend with a 251.2% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.88M | $6.23M | $6.23M | $6.23M | $6.23M | $675.00K | $675.00K | $675.00K | $675.00K | $208.00M | $300.00K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $2.97B | $200.00K | $100.00K | $100.00K |
| QoQ Change | — | +27.7% | +0.0% | +0.0% | +0.0% | -89.2% | +0.0% | +0.0% | +0.0% | >999% | -99.9% | -100.0% | — | — | — | — | — | -100.0% | -50.0% | +0.0% |
| YoY Change | — | — | — | — | +27.7% | -89.2% | -89.2% | -89.2% | -89.2% | >999% | -55.6% | -100.0% | -100.0% | -100.0% | -100.0% | — | — | — | — | — |